Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 1
Submit an article Journal homepage
679
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors

Jan Philipp Bewersdorfa Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0003-3352-0902View further author information
ORCID Icon,
Rory M. Shallisb Yale University and Yale Cancer Center, New Haven, CT, USAORCID Iconhttps://orcid.org/0000-0002-8542-2944View further author information
ORCID Icon,
Andriy Derkachc Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USAView further author information
,
Aaron D. Goldberga Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Anthony Steind City of Hope National Medical Center, Duarte, CA, USAView further author information
,
Eytan M. Steina Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Guido Marcuccid City of Hope National Medical Center, Duarte, CA, USAORCID Iconhttps://orcid.org/0000-0002-3983-5908View further author information
ORCID Icon,
Amer M. Zeidanb Yale University and Yale Cancer Center, New Haven, CT, USAView further author information
,
Shai Shimonye Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Daniel J. DeAngeloe Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Richard M. Stonee Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Ibrahim Aldossd City of Hope National Medical Center, Duarte, CA, USAORCID Iconhttps://orcid.org/0000-0001-9564-4498View further author information
ORCID Icon,
Brian J. Balld City of Hope National Medical Center, Duarte, CA, USAORCID Iconhttps://orcid.org/0000-0001-8625-7023View further author information
ORCID Icon &
Maximilian Stahle Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA, USACorrespondence[email protected]
View further author information
 show all
Pages 188-196 | Received 04 Jul 2022, Accepted 09 Oct 2022, Published online: 26 Oct 2022

References

  • DeWolf S, Tallman MS. How I treat relapsed or refractory AML. Blood. 2020;136(9):1023–1032.
  • Kantarjian H, Kadia T, DiNardo C, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):41.
  • Kantarjian H, Short NJ, DiNardo C, et al. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. Lancet Haematol. 2021;8(12):e922–e33.
  • Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–731.
  • DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-Mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–2398.
  • Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-Mutated AML. N Engl J Med. 2019;381(18):1728–1740.
  • Bewersdorf JP, Giri S, Wang R, et al. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. Haematologica. 2020;105(11):2659–2663.
  • DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401–407.
  • Stahl M, Menghrajani K, Derkach A, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Adv. 2021;5(5):1552–1564.
  • Pollyea DA, Pratz KW, Wei AH, et al. Impact of venetoclax and azacitidine in Treatment-Naïve patients with acute myeloid leukemia and IDH1/2 mutations. Clin Cancer Res. 2022;28(13):2753–2761.
  • DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020;135(2):85–96.
  • Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
  • Abbott D, Cherry E, Amaya M, et al. The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia. Leuk Lymphoma. 2020;62(6):1466–1473.
  • Bewersdorf JP, Derkach A, Gowda L, et al. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leuk Lymphoma. 2021;62(14):3394–3401.
  • DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
  • DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135(11):791–803.
  • Short NJ, DiNardo CD, Daver N, et al. A triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-Mutated acute myeloid leukemia: Results from a phase I/II study. Blood. 2021;138(Supplement 1):696–696.
  • Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1-Mutated acute myeloid leukemia. N Engl J Med. 2022;386(16):1519–1531.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.